Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.

Int J Clin Oncol · 2024 · PMC11129990 · PMID 38582807

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Compared to abiraterone plus ADT, triplet therapy using darolutamide plus docetaxel plus ADT (HR: 0.81, 95%CI 0.62–1.07) and abiraterone plus docetaxel plus ADT (HR: 0.85, 95%CI 0.60–1.20) did not reach statistical significance in terms of improved OS.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.